Increased circulating urotensin II in cirrhosis: Potential implications in liver disease

Peptides

Volumn 29, Issue 5, 2008, Pages 868-872

  Kemp, William ^a,b   Roberts, Stuart ^b   Krum, Henry ^a  

^a NATIONAL HEALTH AND MEDICAL RESEARCH COUNCIL   (Australia)

^b ALFRED HOSPITAL   (Australia)

Author keywords

Cirrhosis; Liver disease; Portal hypertension; Urotensin II

Indexed keywords

ACT 058362; OCTREOTIDE; PALOSURAN; RECEPTOR; RECEPTOR BLOCKING AGENT; SOMATOSTATIN; UNCLASSIFIED DRUG; UROTENSIN II; UROTENSIN II RECEPTOR;

ARTICLE; CHRONIC LIVER DISEASE; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; HUMAN; LIVER CIRRHOSIS; NONHUMAN; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

HUMANS; LIVER CIRRHOSIS; LIVER DISEASES; RECEPTORS, G-PROTEIN-COUPLED; SOMATOSTATIN; UROTENSINS; VASOMOTOR SYSTEM;

EID: 42049108791     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2007.08.020     Document Type: Article

References (49)

1. Abdelrahman A.M., and Pang C.C. Involvement of the nitric oxide/L-arginine and sympathetic nervous systems on the vasodepressor action of human urotensin II in anesthetized rats. Life Sci 71 7 (2002) 819-825
2. Ames R.S., Sarau H.M., Chambers J.K., Willette R.N., Aiyar N.V., Romanic A.M., et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 401 6750 (1999) 282-286
3. Bottrill F.E., Douglas S.A., Hiley C.R., and White R. Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries. Br J Pharmacol 130 8 (2000) 1865-1870
4. Castro A., Jimenez W., Claria J., Ros J., Martinez J.M., Bosch M., et al. Impaired responsiveness to angiotensin II in experimental cirrhosis: role of nitric oxide. Hepatology 18 2 (1993) 367-372
5. Charles C.J., Rademaker M.T., Richards A.M., and Yandle T.G. Urotensin II: evidence for cardiac, hepatic and renal production. Peptides 26 11 (2005) 2211-2214
6. Cheung B.M., Leung R., Man Y.B., and Wong L.Y. Plasma concentration of urotensin II is raised in hypertension. J Hypertens 22 7 (2004) 1341-1344
7. Conlon J.M., Yano K., Waugh D., and Hazon N. Distribution and molecular forms of urotensin II and its role in cardiovascular regulation in vertebrates. J Exp Zool 275 2-3 (1996) 226-238
8. Coulouarn Y., Lihrmann I., Jegou S., Anouar Y., Tostivint H., Beauvillain J.C., et al. Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. Proc Natl Acad Sci USA 95 26 (1998) 15803-15808
9. Douglas S.A., Dhanak D., and Johns D.G. From 'gills to pills': urotensin-II as a regulator of mammalian cardiorenal function. Trends Pharmacol Sci 25 2 (2004) 76-85
10. Douglas S.A., Sulpizio A.C., Piercy V., Sarau H.M., Ames R.S., Aiyar N.V., et al. Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol 131 7 (2000) 1262-1274
11. Douglas S.A., Tayara L., Ohlstein E.H., Halawa N., and Giaid A. Congestive heart failure and expression of myocardial urotensin II. Lancet 359 9322 (2002) 1990-1997
12. Dschietzig T., Bartsch C., Pregla R., Zurbrugg H.R., Armbruster F.P., Richter C., et al. Plasma levels and cardiovascular gene expression of urotensin-II in human heart failure. Regul Pept 110 1 (2002) 33-38
13. Elshourbagy N.A., Douglas S.A., Shabon U., Harrison S., Duddy G., Sechler J.L., et al. Molecular and pharmacological characterization of genes encoding urotensin-II peptides and their cognate G-protein-coupled receptors from the mouse and monkey. Br J Pharmacol 136 1 (2002) 9-22
14. Garcia-Pagan J.C., Bosch J., and Rodes J. The role of vasoactive mediators in portal hypertension. Semin Gastrointest Dis 6 3 (1995) 140-147
15. Gardiner S.M., March J.E., Kemp P.A., and Bennett T. Bolus injection of human UII in conscious rats evokes a biphasic haemodynamic response. Br J Pharmacol 143 3 (2004) 422-430
16. Gardiner S.M., March J.E., Kemp P.A., Davenport A.P., and Bennett T. Depressor and regionally-selective vasodilator effects of human and rat urotensin II in conscious rats. Br J Pharmacol 132 8 (2001) 1625-1629
17. Gardiner S.M., March J.E., Kemp P.A., Maguire J.J., Kuc R.E., Davenport A.P., et al. Regional heterogeneity in the haemodynamic responses to urotensin II infusion in relation to UT receptor localisation. Br J Pharmacol 147 6 (2006) 612-621
18. Gruson D., Rousseau M.F., Ahn S.A., van Linden F., and Ketelslegers J.M. Circulating urotensin II levels in moderate to severe congestive heart failure: its relations with myocardial function and well established neurohormonal markers. Peptides 27 6 (2006) 1527-1531
19. Heller J., Schepke N.F., Neef M., and Sauerbruch T. Octreotide antagonizes the urotensin II (UII) induced aortic contractions in normal and cirrhotic rats. J Hepatol 38 Suppl 2 (2003) 59
20. Heller J., Schepke M., Neef M., Woitas R., Rabe C., and Sauerbruch T. Increased urotensin II plasma levels in patients with cirrhosis and portal hypertension. J Hepatol 37 6 (2002) 767-772
21. Hennenberg M., Biecker E., Trebicka J., Jochem K., Zhou Q., Schmidt M., et al. Defective RhoA/Rho-kinase signaling contributes to vascular hypocontractility and vasodilation in cirrhotic rats. Gastroenterology 130 3 (2006) 838-854
22. Kapoor D., and Sarin S.K. Pathophysiology of portal hypertension. J Gastroenterol Hepatol 17 Suppl (2002) S482-S487
23. Kemp W., Krum H., Colman J., Bailey M., and Richards S.R. Serum urotensin II elevation in chronic liver disease-relationship to severity of cirrhosis and portal hypertension. J Gastro Hepatol 20 Suppl 1 (2005) A86
24. Kemp W., Krum H., Colman J., Yandle T., Richards M., and Roberts S. Urotensin II is a relevant vasoactive mediator of cirrhotic portal hypertension in humans. Hepatology 44 S1 (2006) 202A
25. Kemp W., Roberts S.K., and Krum H. Urotensin II: a vascular mediator in health and disease. Curr Vascular Pharmacol 3 2 (2005) 159-168
26. Leifeld L., Clemens C., Spengler U., Sauerbruch T., and Heller J. Intrahepatic urotensin II expression is down-regulated in liver cirrhosis. J Hepatology 42 Suppl. 2 (2005) 69
27. Liu Q., Pong S.S., Zeng Z., Zhang Q., Howard A.D., Williams Jr. D.L., et al. Identification of urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14. Biochem Biophys Res Commun 266 1 (1999) 174-178
28. Matsushita M., Shichiri M., Imai T., Iwashina M., Tanaka H., Takasu N., et al. Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues. J Hypertens 19 12 (2001) 2185-2190
29. Moller S., Bendtsen F., and Henriksen J.H. Vasoactive substances in the circulatory dysfunction of cirrhosis. Scand J Clin Lab Invest 61 6 (2001) 421-429
30. Newby D.E., and Jalan R. Urotensin II: better than somatostatin for portal hypertension?. Hepatology 31 5 (2000) 1201-1202
31. Ng L.L., Loke I., O'Brien R.J., Squire I.B., and Davies J.E. Plasma urotensin in human systolic heart failure. Circulation 106 23 (2002) 2877-2880
32. Nothacker H.P., Wang Z., McNeill A.M., Saito Y., Merten S., O'Dowd B., et al. Identification of the natural ligand of an orphan G-protein-coupled receptor involved in the regulation of vasoconstriction. Nat Cell Biol 1 6 (1999) 383-385
33. Pizcueta M.P., Casamitjana R., Bosch J., and Rodes J. Decreased systemic vascular sensitivity to norepinephrine in portal hypertensive rats: role of hyperglucagonism. Am J Physiol 258 2 Pt 1 (1990) G191-G195
34. Pugh R.N., Murray-Lyon I.M., Dawson J.L., Pietroni M.C., and Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60 8 (1973) 646-649
35. Richards A.M., Nicholls M.G., Lainchbury J.G., Fisher S., and Yandle T.G. Plasma urotensin II in heart failure. Lancet 360 9332 (2002) 545-546
36. Russell F.D., Meyers D., Galbraith A.J., Bett N., Toth I., Kearns P., et al. Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure. Am J Physiol Heart Circ Physiol 285 4 (2003) H1576-H1581
37. Sauzeau V., Le Mellionnec E., Bertoglio J., Scalbert E., Pacaud P., and Loirand G. Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase. Circ Res 88 11 (2001) 1102-1104
38. Shah V. Cellular and molecular basis of portal hypertension. Clin Liver Dis 5 3 (2001) 629-644
39. Song W., Abdel-Razik A.E., Lu W., Ao Z., Johns D.G., Douglas S.A., et al. Urotensin II and renal function in the rat. Kidney Int 69 8 (2006) 1360-1368
40. Totsune K., Takahashi K., Arihara Z., Sone M., Ito S., and Murakami O. Increased plasma urotensin II levels in patients with diabetes mellitus. Clin Sci (Lond) 104 1 (2003) 1-5
41. Totsune K., Takahashi K., Arihara Z., Sone M., Murakami O., Ito S., et al. Elevated plasma levels of immunoreactive urotensin II and its increased urinary excretion in patients with Type 2 diabetes mellitus: association with progress of diabetic nephropathy. Peptides 25 10 (2004) 1809-1814
42. Totsune K., Takahashi K., Arihara Z., Sone M., Satoh F., Ito S., et al. Role of urotensin II in patients on dialysis. Lancet 358 9284 (2001) 810-811
43. Trebicka J., Hennenberg M., Eckhardt A., Biecker E., Sauerbruch T., and Heller J. Urotensin II receptor antagonist Palosuran lowers portal pressure and improves renal perfusion in cirrhotic rats. Hepatology 44 S1 (2006) 202A
44. Watanabe T., Kanome T., Miyazaki A., and Katagiri T. Human urotensin II as a link between hypertension and coronary artery disease. Hypertens Res 29 6 (2006) 375-387
45. Wiest R., and Groszmann R.J. Nitric oxide and portal hypertension: its role in the regulation of intrahepatic and splanchnic vascular resistance. Semin Liver Dis 19 4 (1999) 411-426
46. Wiest R., Shah V., Sessa W.C., and Groszmann R.J. NO overproduction by eNOS precedes hyperdynamic splanchnic circulation in portal hypertensive rats. Am J Physiol 276 4 Pt 1 (1999) G1043-G1051
47. Zhang A.Y., Chen Y.F., Zhang D.X., Yi F.X., Qi J., Andrade-Gordon P., et al. Urotensin II is a nitric oxide-dependent vasodilator and natriuretic peptide in the rat kidney. Am J Physiol Renal Physiol 285 4 (2003) F792-F798
48. Zhou Q., Hennenberg M., Trebicka J., Jochem K., Leifeld L., Biecker E., et al. Intrahepatic upregulation of RhoA and Rho-kinase signaling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis. Gut 55 9 (2006) 1296-1305
49. Zhu Y.C., Zhu Y.Z., and Moore P.K. The role of urotensin II in cardiovascular and renal physiology and diseases. Br J Pharmacol 148 7 (2006) 884-901